Even though the Norwegian Directorate of Health has bought 8640 treatments with the corona pill from Merck, Norway will probably not use it, says director of health Bjørn Guldvog.
Among the reasons is that the specialist health service in Norway is so good, and that patients who are infected with covid-19 do not have a better prognosis if they receive the medicine, writes NRK.
– We do not think it helps to improve the outlook, so there is no reason to use it. There were promising results in the first part of the studies, but in the second part the results were less promising, says Guldvog.
France has canceled the medicine after a new study gave worse results than first thought, and in Denmark doctors think the medicine is too bad for their patients, according to the state channel.
Approved for emergency use
In November, the European Medicines Agency (EMA) opened for emergency use of corona medicine, which meant that it could also be used in Norway.
– We can use it in special contexts, but preliminary assessments have been made which indicate that we do not recommend that they be used extensively in the primary health care service. Then we look for whether there may be subgroups that can benefit from the medicine, says Guldvog.
The medicine has previously been approved in the United Kingdom, while the United States has approved it for emergency use. The European Medicines Agency (EMA) is considering whether the pill should be given a final, formal approval.
Has printed hundreds of prescriptions for coronary heart disease: «People are calling from all over the country»
Studies done on unvaccinated
Merck’s corona pill goes by the name Lagevrio and contains the drug molnupiravir.
The company stated in early October that this medicine could halve the risk of hospitalization and death.
It is uncertain how the drug works for the vaccinated as the few studies that have been done have been done on the unvaccinated. Then the results showed that the risk of hospitalization and death fell by 30 percent among those who risk a serious course of the disease.